VIMTALABS.NS
Strong BuyPremium GrowerAI neutralVimta Labs Limited · Healthcare · India · $278M cap · $853K/day traded
INR 521.65 -3.5% · close 15 Oct · scored 17 Oct
StockRank down 2.2 since 16 Oct: Momentum down 3.
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 17 Oct 2026, MoatMap's StockRank for Vimta Labs Limited (VIMTALABS.NS) is 86/100, ranked against 24,000+ stocks in 35 markets (Quality 84, Value 34, Momentum 66, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Vimta Labs is an Indian contract research and testing laboratory serving pharmaceutical, food and environmental clients, with strong returns on capital and good share price momentum. Testing demand is growing as drug makers outsource more work to India, but the shares already trade at a high valuation, and the news gives no specific evidence of an upcoming earnings acceleration.
ABOUT VIMTA LABS LIMITED
Read
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical...
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.2B | 2.9B | 3.4B | 4.1B | 8.9% | 4.2B |
| EPS (INR) | 10.89 | 9.26 | 15.14 | 17.40 | 16.9% | 17.66 |
| Shares | 44.3M | 44.3M | 44.5M | 44.7M | +0.9% | 44.7M |
| Debt | 149.9M | 191.9M | 85.2M | 33.3M | -39.4% | 33.3M |
| Equity | 2.8B | 3.1B | 3.8B | 4.6B | 17.5% | — |
| Op CF | 879.4M | 608.9M | 940.5M | 1.5B | 18.7% | 1.5B |
| Inv CF | -572.6M | -760.5M | -755.4M | -1.3B | — | — |
| Fin CF | -109.8M | -19.0M | -161.2M | -103.5M | — | — |
No new 52-week low for 27 weeks, 39% above that low, but not back above a rising 50-day average.
The Momentum score still reads 66: it looks back six months, so it has not caught up with this fall.
Swung more than 54% of stocks we rank over the past year (44% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VIMTALABS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VIMTALABS.NS | Vimta Labs Limited(you) | $278M | 86 | Strong Buy |
| SURAKSHA.NS | Suraksha Diagnostic Limited | $193M | 70 | Buy |
| KRSNAA.NS | Krsnaa Diagnostics Limited | $186M | 69 | Buy |
| THYROCARE.NS | Thyrocare Technologies Limited | $940M | 86 | Strong Buy |
| METROPOLIS.NS | Metropolis Healthcare Limited | $1.3B | 78 | Buy |
| VIJAYA.NS | Vijaya Diagnostic Centre Limited | $1.6B | 72 | Buy |
| LALPATHLAB.NS | Dr. Lal PathLabs Limited | $3.4B | 79 | Buy |
| SYNGENE.NS | Syngene International Limited | $1.6B | 56 | Hold |
| SAILIFE.NS | Sai Life Sciences Limited | $3.5B | 66 | Buy |
| INDRAMEDCO.NS | Indraprastha Medical Corporation Limited | $354M | 84 | Strong Buy |
Peer medians: ROE 11.7% · P/E 40.7x · Gross margin 59.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.